{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:54:00Z","timestamp":1787583240267,"version":"build-2736575974"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005893","name":"China Academy of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005893","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    Compound Kushen injection (CKI) combined with intraperitoneal chemotherapy (IPC) is widely used in the treatment of malignant ascites (MA). However, evidence about its efficacy and safety remains limited. This review aimed to evaluate the efficacy and safety of CKI combined with IPC for the treatment of MA.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Protocol of this review was registered in PROSPERO (CRD42022304259). Randomized controlled trials (RCTs) on the efficacy and safety of IPC with CKI for the treatment of patients with MA were searched through 12 electronic databases and 2 clinical trials registration platforms from inception until 20 January 2023. The Cochrane risk-of-bias tool was used to assess the quality of the included trials through the risk of bias assessment. We included RCTs that compared IPC single used or CKI combined with IPC for patients with MA schedule to start IPC. The primary outcome was identified as an objective response rate (ORR), while the secondary outcomes were identified as the quality of life (QoL), survival time, immune functions, and adverse drug reactions (ADRs). The Revman5.4 and Stata17 software were used to calculate the risk ratio (RR) at 95% confidence intervals (CI) for binary outcomes and the mean difference (MD) at 95% CI for continuous outcomes. The certainty of the evidence was assessed according to the GRADE criteria.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 17 RCTs were assessed, which included 1200 patients. The risk of bias assessment of the Cochrane risk-of-bias tool revealed that one study was rated high risk and the remaining as unclear or low risk. Meta-analysis revealed that CKI combined with IPC had an advantage in increasing ORR (RR = 1.31, 95% CI 1.20 to 1.43,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.00001) and QoL (RR = 1.50, 95% CI 1.23 to 1.83,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001) when compared with IPC alone. Moreover, the combined treatment group showed a lower incidence of myelosuppression (RR = 0.51, 95%CI 0.40\u20130.64,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.00001), liver dysfunction (RR = 0.33, 95%CI 0.16 to 0.70,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004), renal dysfunction (RR = 0.39, 95%CI 0.17 to 0.89,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.02), and fever (RR = 0.51, 95%CI 0.35 to 0.75,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0007) compared to those of the control group. The quality of evidence assessment through GRADE criteria showed that ORR, myelosuppression, and fever were rated moderate, renal dysfunction and liver dysfunction were rated low, and QoL and abdominal pain were rated very low.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The efficacy and safety of CKI combined with IPC were superior to that with IPC alone for the treatment of MA, which indicates the potentiality of the treatment. However, more high-quality RCTs are required to validate this conclusion.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    [\n                    <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022304259<\/jats:ext-link>\n                    ], identifier [PROSPERO 2022 CRD42022304259].\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1036043","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T23:27:00Z","timestamp":1677799620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of efficacy and safety for compound kushen injection combined with intraperitoneal chemotherapy for patients with malignant ascites: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Hui-Bo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Juan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Tai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Tai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual. Life Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","article-title":"A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites","volume":"79","author":"Barni","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: Pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.16073\/j.cnki.cjcpt.2021.16.09","article-title":"Clinical study of compound kushen injection combined with oxaliplatin and tigio in the treatment of stage \u2163 gastric cancer","volume":"28","author":"Chang","year":"2021","journal-title":"Chin. J. Cancer Prev. Treat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3969\/j.issn.1009-0460.2019.09.018","article-title":"Progression of recombinant human endostatin (endostar) intraperitoneal injection for the treatment of malignant ascites","volume":"24","author":"Chao","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3969\/j.issn.1674-6805.2011.17.009","article-title":"Matrine injection and intraperitoneal injection of cisplatin efficacy in treatment of cancer ascites","volume":"9","author":"Chen","year":"2011","journal-title":"Chin. FOREIGN Med. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"114914","DOI":"10.1016\/j.jep.2021.114914","article-title":"Research progress of matrine's anticancer activity and its molecular mechanism","volume":"286","author":"Chen","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.7150\/jca.40267","article-title":"Compound kushen injection combined with platinum-based chemotherapy for stage III\/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.14009\/j.issn.1672-2124.2011.04.016","article-title":"Compound kusheng injection combined with cisplatin for malignant pleural effusion: A clinical study","volume":"11","author":"Chen","year":"2011","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3969\/j.issn.1671-038X.2006.06.022","article-title":"Treatment of malignant ascites with intraperitoneal injection of compound Kushen injection combined cisplatin in 34 patients","volume":"14","author":"Cheng","year":"2006","journal-title":"Chin. J. Integr. Tradit. West Med. Dig."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/cncr.32826","article-title":"The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations","volume":"126","author":"Chicago Consensus Working","year":"2020","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12885-018-5230-8","article-title":"Cell cycle, energy metabolism and DNA repair pathways in cancer cells are suppressed by Compound Kushen Injection","volume":"19","author":"Cui","year":"2019","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.6039\/j.issn.1001-0408.2020.06.19","article-title":"Meta-analysis of the efficacy and safety of different administration routes of Bevacizumab in the treatment of malignant pleural effusion","volume":"31","author":"Dai","year":"2020","journal-title":"China Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41598-017-18325-7","article-title":"Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation","volume":"8","author":"Gao, L","year":"2018","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3969\/j.issn.1672-4992.2018.15.020","article-title":"Therapeutic effect of compound Kushen injection and Lobaplatin in treating malignant ascites","volume":"26","author":"Gao, S. T","year":"2018","journal-title":"J. Mod. Oncol."},{"key":"B17","first-page":"1955","article-title":"Investigating the anti-angiogenic effects of Fufang Kushen Injection in combination with cisplatin using a zebrafish model","volume":"33","author":"Han","year":"2020","journal-title":"Pak J. Pharm. Sci."},{"key":"B18","first-page":"252","article-title":"Intraperitoneal injection of recombinant human endostatin combined with fluorouracil on advanced cancers with malignant ascites","volume":"14","author":"He","year":"2009","journal-title":"Chin. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"B20","first-page":"1593","article-title":"Treatment of malignant ascites with intraperitoneal injection of compound Kushen injection combined cisplatin in 90 patients","volume":"19","author":"Huang","year":"2010","journal-title":"Chin. J. New Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-9691.2018.05.023","article-title":"Effect of compound Kushen injection combined with oxaliplatin chemotherapy on clinical efficacy of patients with primary hepatocellular cancer","volume":"25","author":"Huang","year":"2018","journal-title":"Chin. J. Integr. Tradit. West Med. Intensive Crit. Care"},{"key":"B22","unstructured":"Cochrane handbook for systematic reviews of interventions\n            JulianH.\n            JamesT.\n            JacQuelineC.\n            MirandaC.\n            TianjingL.\n            MatthewP.\n          2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3969\/j.issn.1672-4992.2015.10.34","article-title":"Clinical efficacy of intraperitoneal perfusion of compound matrine injection and cisplatin on malignant ascites","volume":"23","author":"Jia","year":"2015","journal-title":"J. Mod. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.3969\/j.issn.1008-8849.2018.33","article-title":"Effect of compound kushen injection on abdominal perfusion of malignant ascites and influence on CEA, CA125 and AFP","volume":"27","author":"Jiang","year":"2018","journal-title":"Mod. J. Integr. Tradit. Chin. West Med."},{"key":"B25","first-page":"446","article-title":"Cytopathologic interpretation of ascites due to malignancy","volume":"17","author":"Kalogeraki","year":"2012","journal-title":"J. BUON"},{"key":"B26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7150\/jca.66410","article-title":"Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"J. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.13194\/j.issn.1673-842x.2016.11.042","article-title":"Observation of paclitaxel liposome fufang kushen injection and yiqi yangwei decoction combined with in the treatment of advanced gastric cancer with malignant ascites","volume":"18","author":"Li","year":"2016","journal-title":"J. Liaoning Univ. Tradit. Chin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.joim.2020.02.004","article-title":"Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)","volume":"18","author":"Ling","year":"2020","journal-title":"J. Integr. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"572396","DOI":"10.3389\/fphar.2020.572396","article-title":"Comparative efficacy and safety of Chinese herbal injections combined with cyclophosphamide and 5-fluorouracil chemotherapies in treatment of breast cancer: A bayesian network meta-analysis","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3969\/j.issn.1672-2809.2018.09.011","article-title":"Effects of matrine injection combined with GC chemotherapy on chemo tolerance and median survival time in patients with advanced bladder cancer","volume":"15","author":"Liu","year":"2018","journal-title":"Drug Eval."},{"key":"B31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.13194\/j.issn.1673-842x.2016.10.068","article-title":"Analysis of nursing effect of compound matrine injection combined with chemotherapeutic drugs intraperitoneal injection in the treatment of liver cancer with malignant ascites","volume":"18","author":"Ma","year":"2016","journal-title":"J. Liaoning Univ. Tradit. Chin. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fphar.2016.00070","article-title":"The therapeutic efficacy and safety of compound kushen injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An update systematic review and meta-analysis","volume":"7","author":"Ma","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting Items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207:aid-cncr2820470134>3.0.co;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"B36","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fonc.2019.00314","article-title":"Effect of compound kushen injection, a natural compound mixture, and its identified chemical components on migration and invasion of colon, brain, and breast cancer cell lines","volume":"9","author":"Nourmohammadi","year":"2019","journal-title":"Front. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7241927","DOI":"10.1155\/2019\/7241927","article-title":"Compound kushen injection as an adjunctive therapy for the treatment of non-small-cell lung cancer: A meta-analysis of randomized controlled trials","volume":"2019","author":"Pu","year":"2019","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"B39","unstructured":"Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry\n            ServicesU.\n            AdministrationF.\n            ExcellenceO.\n            Cder)C.\n            CberC.\n          2018"},{"key":"B40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fonc.2019.00632","article-title":"Understanding the mechanistic contribution of herbal extracts in compound kushen injection with transcriptome analysis","volume":"9","author":"Shen","year":"2019","journal-title":"Front. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3969\/j.issn.1009-7147.2009.02.024","article-title":"Effect of compound kushen combined with intraperitoneal chemotherapy on ovarian cancer ascites","volume":"14","author":"Sun","year":"2009","journal-title":"ZHEJIANG J. Trauma. Surg."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.16680\/j.1671-3826.2015.12.14","article-title":"United Fufangkushen paclitaxel liposome injection in the treatment of malignant ascites efficacy and safety analysis","volume":"43","author":"Tang","year":"2015","journal-title":"Clin. J. Med. Off."},{"key":"B43","volume-title":"Compound kushen injection combined with cisplatin in the treatment of malignant intraperitoneal perfusion:A Meta-analysis","author":"Tang","year":"2020"},{"key":"B44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3969\/j.issn.1002-2406.2017.03.023","article-title":"Effect of compound kushen injection combined with intraperitoneal chemotherapy in the treatment of malignant ascites and its effect on CEA, CA125 and AFP levels","volume":"34","author":"Tao","year":"2017","journal-title":"Inf. Traditional Chin. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3969\/j.issn.1004-745X.2017.12.028","article-title":"Treatment status and progress of malignant ascites","volume":"26","author":"Wang","year":"2017","journal-title":"J. Emerg. Traditional Chin. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3892\/ol.2018.9861","article-title":"Effects of compound Kushen injection on pathology and angiogenesis of tumor tissues","volume":"17","author":"Wang","year":"2019","journal-title":"Oncol. Lett."},{"key":"B47","volume-title":"Traditional Chinese medicine injections combined with cisplatin intraperitoneal perfusion in the treatment of cancerous ascites: A systematic review and meta-analysis","author":"Wang","year":"2020"},{"key":"B48","doi-asserted-by":"publisher","first-page":"153781","DOI":"10.1016\/j.phymed.2021.153781","article-title":"Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating beta-catenin\/c-Myc signaling","volume":"93","author":"Wang, K. X","year":"2021","journal-title":"Phytomedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.13699\/j.cnki.1001-6821.2021.17.018","article-title":"Anti-tumor effect of marine adjuvant chemotherapy in hepatoma ascites tumor-bearing mice","volume":"37","author":"Wang, Q. G","year":"2021","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: Bridging the divide","volume":"16","author":"Wilson","year":"","journal-title":"Lancet Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: The past, present, and future","volume":"16","author":"Wilson","year":"","journal-title":"Lancet Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13020-021-00534-y","article-title":"A network pharmacology approach to reveal the pharmacological targets and biological mechanism of compound kushen injection for treating pancreatic cancer based on WGCNA and in vitro experiment validation","volume":"16","author":"Wu","year":"2021","journal-title":"Chin. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14163\/j.cnki.11-5547\/r.2018.30.064","article-title":"Clinical trial of compound kushen injection combined with cisplatin and single cisplatin in the treatment of hepatocellular carcinoma with malignant ascites","volume":"13","author":"Wu","year":"2018","journal-title":"China Pract. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"114690","DOI":"10.1016\/j.jep.2021.114690","article-title":"Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H\/P309S mutant colorectal cancer cells through inducing apoptosis","volume":"283","author":"Wu","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.16680\/j.1671-3826.2018.07.01","article-title":"Observation on the curative effect of oxycontin combined with compound sophorae injection an cancer pain in patients with adcanced liver cancer","volume":"46","author":"Xia","year":"2018","journal-title":"Clin. J. Med. Off."},{"key":"B56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.14009\/j.issn.1672-2124.2012.02.014","article-title":"Efficacy and toxicity of compound matrine injection combined with gemcitabine plus cisplatin for advanced non-small-cell lung cancer: Analysis of 56 cases","volume":"12","author":"Xiao","year":"2012","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3969\/j.issn.2095-1264.2014.079","article-title":"Compound kushen injection plus intraperitoneal chemotherapy in the treatment of malignant ascites:a meta-analysis","volume":"4","author":"Xu","year":"2014","journal-title":"Anti-Tumor Pharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"881","DOI":"10.16073\/j.cnki.cjcpt.2019.12.012","article-title":"Efficacy and side effect of compound Sophora flavescens injection in adjuvant folfox chemotherapy for gastric cancer: A systematic review","volume":"26","author":"Xun","year":"2019","journal-title":"Chin. J. Cancer Prev. Treat."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.13193\/j.issn.1673-7717.2018.10.056","article-title":"Effect of compound kushen injection and neoadjuvant chemotherapy on cervical cancer and survival","volume":"36","author":"Yang","year":"2018","journal-title":"Chin. Arch. Tradit. Chin. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.3390\/ijms221910827","article-title":"Natural products with activity against lung cancer: A review focusing on the tumor microenvironment","volume":"22","author":"Yang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e000317","DOI":"10.1136\/jitc-2019-000317","article-title":"Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib","volume":"8","author":"Yang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00520-013-2063-5","article-title":"A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain","volume":"22","author":"Yanju","year":"2014","journal-title":"Support Care Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"300060519898336","DOI":"10.1177\/0300060519898336","article-title":"Systematic review and network meta-analysis comparing Chinese herbal injections with chemotherapy for treating patients with esophageal cancer","volume":"48","author":"Zhang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"109169","DOI":"10.1016\/j.biopha.2019.109169","article-title":"An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K\/Akt\/mTOR pathway and up regulating autophagy in non-small cell lung cancer","volume":"118","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.13422\/j.cnki.syfjx.2016110179","article-title":"Combination of compound kushen injection and cisplatin intraperitoneal chemotherapy in patients with gastric cancer and malignant ascites","volume":"22","author":"Zhang","year":"2016","journal-title":"Chin. J. Exp. Tradit. Med. Formulae"},{"key":"B66","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3870\/j.issn.1674-4616.2012.03.005","article-title":"Clinical observation of compound matrine injection in treatment of malignant ascites by intraperitoneal perfusion","volume":"4","author":"Zhang","year":"2012","journal-title":"Res. Integr. Traditional Chin. West. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"601","DOI":"10.14009\/j.issn.1672-2124.2015.05.015","article-title":"Effiacy and safety of compound kushen injection plus nedaplatin for malignant pleural effusion in patients with lung cancer","volume":"15","author":"Zhang","year":"2015","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.21037\/jgo-21-774","article-title":"A systematic review and meta-analysis on the efficacy of Compound Kushen Injection in 3 kinds of digestive tract tumor","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3969\/j.issn.1003-8914.2020.15.038","article-title":"Effect of compound kushen injection and cisplatin on immune function and vascular endothelial function in patients with malignant ascites","volume":"35","author":"Zhang","year":"2020","journal-title":"Guangming J. Chin. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"68873","DOI":"10.18632\/oncotarget.20320","article-title":"Comparative efficacy and safety of Chinese herbal injections combined with the FOLFOX regimen for treating gastric cancer in China: A network meta-analysis","volume":"8","author":"Zhang, D","year":"2017","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3760\/cma.j.issn.1008-6706.2017.15.010","article-title":"Therapeutic effect of losecplatin combined with compound matrine in the intraperitoneal perfusion treatment of ovarian cancer with malignant ascites and its effect on TNF","volume":"24","author":"Zhang, T","year":"2017","journal-title":"Chin. J. Prim. Med. Pharm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3969\/j.issn.1005-5304.2012.08.049","article-title":"Progress in the experimental study of antitumor effect and mechanism of compound kushen injection","volume":"19","author":"Zhang, W. J","year":"2012","journal-title":"Chin. J. Inf. Tradit. Chin. Med."},{"key":"B73","first-page":"343","article-title":"Effect of compound kushen injection in the treatment on Ehrlich ascites carcinoma in mice","volume":"35","author":"Zhang, Y","year":"2012","journal-title":"Drug Eval. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2014.08.037","article-title":"Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways","volume":"355","author":"Zhao","year":"2014","journal-title":"Cancer Lett."},{"key":"B75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0254-6272(16)30002-4","article-title":"Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy","volume":"36","author":"Zhao","year":"2016","journal-title":"J. Tradit. Chin. Med."},{"key":"B76","first-page":"165","article-title":"Effect of anti-VEGF in the treatment of malignant ascites","volume":"7","author":"Zhong","year":"2015","journal-title":"J. Dig. Oncol. Version)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.13192\/j.issn.1000-1719.2022.02.037","article-title":"Clinical study of compound kushen injection combined with carboplatin intraperitoneal perfusion in the treatment of malignant peritoneal effusion","volume":"49","author":"Zhou","year":"2022","journal-title":"Liaoning J. Tradit. Chin. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.3390\/molecules17066481","article-title":"Antioxidant and immunity activities of fufang kushen injection liquid","volume":"17","author":"Zhou","year":"2012","journal-title":"Molecules"},{"key":"B79","doi-asserted-by":"publisher","first-page":"742421","DOI":"10.3389\/fcell.2021.742421","article-title":"An advanced systems pharmacology strategy reveals AKR1B1, MMP2, PTGER3 as key genes in the competing endogenous RNA network of compound kushen injection treating gastric carcinoma by integrated bioinformatics and experimental verification","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1036043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T23:27:40Z","timestamp":1677799660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1036043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":79,"alternative-id":["10.3389\/fphar.2023.1036043"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1036043","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"article-number":"1036043"}}